8-K: Microbot Medical Showcases LIBERTY System at SIO Meeting

Microbot Medical Inc. announced its participation in the Society of Interventional Oncology annual meeting to accelerate commercial adoption of its LIBERTY Endovascular Robotic System.

Summary

• Microbot Medical Inc. is attending the Society of Interventional Oncology (SIO) annual meeting in Savannah, GA, from February 4-8, 2026.
• The company will leverage the conference, which occurs during the limited market release of its LIBERTY Endovascular Robotic System, to share practical insights and personal experiences from physicians who have used the system.
• This event marks the first commercial exhibition of the LIBERTY System since its limited market release commenced in late 2025, aiming to accelerate commercial awareness and adoption among interventional oncologists.
• Microbot Medical will offer hands-on live demonstrations of the LIBERTY System, which is an FDA-cleared, single-use, remotely operated robotic system designed for precise vascular navigation while reducing radiation exposure and physical strain.
• A full market release of the LIBERTY System is planned for April 2026, coinciding with the Society of Interventional Radiology (SIR) conference.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive operational update, indicating the company is actively pursuing its commercialization strategy for the LIBERTY System, which is crucial for a medical device company in its early market release phase.

Positives

• The SIO conference provides a valuable platform to share physician experiences and insights, which is crucial for driving commercial adoption of the LIBERTY System.
• This marks the first commercial exhibition of the LIBERTY System, allowing direct engagement with interventional oncologists to build awareness and accelerate adoption.
• The LIBERTY System is highlighted as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, indicating a differentiated market position.
• The system targets a large and expanding multi-billion dollar market, with interventional oncology identified as a key value driver.
• Significant increases in interventional oncology procedure volumes over the past decade suggest strong demand for advanced technologies like LIBERTY.

Risks

• Market conditions may impact the commercial success of the LIBERTY Endovascular Robotic System.
• Inherent risks exist in the commercialization of the LIBERTY System and in the development of future versions or applications.
• Uncertainty surrounds the results of regulatory pathways and the timing of regulatory approvals.
• Political, social, and geopolitical conditions, including changes in personnel or procedures at the FDA, could create uncertainty.
• Announcements of tariffs on imports into the U.S. could affect operations.
• Disruptions from new and ongoing hostilities between Israel and the Palestinians, Iran, and other neighboring countries pose risks.
• Maintaining intellectual property rights is crucial and subject to potential challenges.

Future Outlook

The company expects engagement with interventional oncologists and sharing user experiences at the SIO conference to support the commercial traction of the LIBERTY System ahead of its full market release planned for April 2026. The LIBERTY System targets a large and expanding multi-billion dollar market, driven by increasing interventional oncology procedure volumes.

Management Comments

• "LIBERTY represents a new and differentiated robotic solution, targeting a large and expanding multi-billion dollar market, with interventional oncology serving as a key value driver in interventional radiology."
• "Interventional oncology procedure volumes have increased significantly over the past decade, which we believe has created strong demand for advanced technologies such as LIBERTY."
• "Engagement with interventional oncologists, including sharing user experience and reinforcing the breadth of LIBERTYs functionality, is expected to support the commercial traction of LIBERTY ahead of the full market release which is planned for April."

Industry Context

StockSavvy.ai notes that the interventional oncology market is experiencing significant growth, driven by advancements in minimally invasive procedures. Microbot Medical's participation in the SIO conference and the showcasing of its FDA-cleared LIBERTY System positions it to capitalize on this trend, particularly as robotic assistance becomes more prevalent in complex endovascular interventions. The focus on user experience sharing is a common strategy in MedTech to build confidence and accelerate adoption among specialists.

Comparison to Industry Standards

• LIBERTY is highlighted as the "only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures," suggesting a unique market position compared to multi-use or non-remotely operated systems from competitors like Intuitive Surgical (da Vinci system, primarily for general surgery, urology, gynecology) or Medtronic (Hugo RAS system, also for general surgery).
• The "multi-billion dollar market" for interventional oncology procedures aligns with broader industry estimates for the growth of minimally invasive cancer treatments, which are often compared to traditional open surgeries in terms of patient recovery and outcomes.
• The significant increase in interventional oncology procedure volumes over the past decade is consistent with global trends in cancer care shifting towards less invasive and more targeted therapies.

Stakeholder Impact

• Shareholders: Potential for increased revenue and market penetration if commercial adoption is successful, leading to long-term value creation.
• Customers (Physicians/Hospitals): Access to a new FDA-cleared robotic system designed to improve precision, efficiency, and safety in endovascular procedures, potentially reducing radiation exposure and physical strain.
• Patients: Potential for improved outcomes and safer procedures due to advanced robotic technology.

Next Steps

• Continue sharing practical insights and personal experiences from physicians using the LIBERTY System.
• Engage directly with interventional oncologists to accelerate commercial awareness and adoption.
• Offer hands-on live demonstrations of the LIBERTY System.
• Full market release of the LIBERTY System planned for April 2026 at the Society of Interventional Radiology (SIR) conference.

Key Dates

Recommendation

The filing provides a positive update on commercialization efforts for a key product, the LIBERTY System, which is an important step for a medical device company. However, it does not contain new financial results or significant unexpected developments that would warrant a 'buy' or 'strong buy' recommendation. The company is executing its stated strategy, and while the market opportunity is large, successful adoption and financial performance remain to be proven. The identified risks also warrant caution. Therefore, a 'hold' recommendation is appropriate as investors await further progress on the full market release and subsequent financial reporting.

Keywords

Microbot Medical, LIBERTY System, Endovascular Robotics, Interventional Oncology, Medical Devices, FDA Cleared, Robotic Surgery, Healthcare Technology, MBOT